Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Inclusion Criteria: * Histologically or cytologically documented, unresectable, locally advanced or metastatic solid tumor * Must have available archived tumor tissue (formalin-fixed paraffin-embedded) \[FFPE\]. * 18 years of age or older. * Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) or increased CA-125 (ovarian cancer) or PSA (prostate cancer) and/or CA 19-9 (pancreatic cancer). * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. * Have adequate organ function * Able to take oral medications. * Willing and able to provide informed consent. * Sexually active patients must be willing to use an acceptable method of contraception. * Females of childbearing potential must have a negative serum pregnancy test at screening. * Willing and able to comply with all study procedures. Part 2 Dose Expansion Tumor Types: * Breast and ovarian cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 4 prior regimens for metastatic disease. * Prostate or pancreatic cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 2 prior regimens for metastatic disease. * Small cell lung cancer (SCLC) patients who have received no more than one prior regimen for SCLC. * Ewing's sarcoma patients who have received no more than 3 prior regimens for metastatic disease. Exclusion Criteria: * Part 2 Expansion: Prior treatment with a PARP inhibitor. * Has history of central…